CARsgen Therapeutics Holdings Limited (OTCMKTS:CRTHF – Get Free Report)’s stock price traded down 14.3% during trading on Friday . The stock traded as low as $1.62 and last traded at $1.62. Approximately 1,500 shares traded hands during trading, a decline of 46% from the average daily volume of 2,800 shares. The stock had previously closed at $1.8895.
CARsgen Therapeutics Price Performance
The business has a 50-day simple moving average of $1.95 and a two-hundred day simple moving average of $1.80.
About CARsgen Therapeutics
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).
See Also
- Five stocks we like better than CARsgen Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for CARsgen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARsgen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
